Firsocostat, Allosteric acetyl-CoA carboxylase inhibitor (TBI4699)
$135.00 – $423.00
Allosteric acetyl-CoA carboxylase inhibitor
SKU | Stock | SIZE (mg) | Price | Quantity | ||
---|---|---|---|---|---|---|
TBI4699-5MG | Yes | 5 MG | $135.00 | |||
TBI4699-25MG | Yes | 25 MG | $423.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Product Details
Formal Name: 2-[1-[(2R)-2-(2-Methoxyphenyl)-2-9oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic acid
Alternate Names: ND-630; NDI-010976; GS-0976
Molecular Formula: C28H31N3O8S
Formula Weight: 569.63
CAS Number: 1434635-54-7
Purity: >98%
Formulation: powder
Solubility: Soluble in DMSO (up to at least 25 mg/ml)
Storage: -20°C
Stability: ≥ 2 years.
Applications
Allosteric acetyl-CoA carboxylase inhibitor
Functions
Potent (IC50 = 1.7 nM ACC1; 2.6 nM ACC2) allosteric protein-protein interaction inhibitor of acetyl-CoA carboxylase (ACC). It interacts with the ACC phosphopeptide acceptor and dimerization site to inhibit enzymatic activity resulting in decreased fatty acid synthesis and stimulation of fatty acid oxidation. It reduced hepatic steatosis, improves insulin sensitivity, reduces weight gain, and favorably affects dyslipidemia in rats. Firsocostat decreased hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Directly impairs profibrinogenic activity of hepatic stellate cells (HSC) via prevention of induction of glycolysis and oxidative phosphorylation during HSC activation.
Application Procedures
First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.
Additional information
SIZE (mg) | 25 MG, 5 MG |
---|
Be the first to review “Firsocostat, Allosteric acetyl-CoA carboxylase inhibitor (TBI4699)”
You must be logged in to post a review.
Reviews
There are no reviews yet.